These findings are in agreement with reports showing that the use of C5aR antagonists is protective in acute models of colitis induced by DSS or by 2,4,6-trinitrobenzene sulfonic acid administration, which mimics the pathology of CD (47–49). This evidence concerns the gene C5AR1 and colitis.